Ceftriaxone and Linzess drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftriaxone (ceftriaxone sodium) and Linzess (linaclotide). Common drug interactions include fatigue among females and abdominal distension among males.

The phase IV clinical study analyzes what interactions people have when they take Ceftriaxone and Linzess. It is created by eHealthMe based on reports of 49 people who take the same drugs from the FDA, and is updated regularly.

What is Ceftriaxone?

Ceftriaxone has active ingredients of ceftriaxone sodium. It is often used in typhoid fever. eHealthMe is studying from 40,991 Ceftriaxone users. Check the latest studies of Ceftriaxone.

What is Linzess?

Linzess has active ingredients of linaclotide. It is often used in constipation. eHealthMe is studying from 24,086 Linzess users. Check the latest studies of Linzess.



On Jul, 20, 2026

49 people who take Ceftriaxone and Linzess together, and have interactions are studied.

Ceftriaxone and Linzess drug interactions.

What are the common drug interactions of Ceftriaxone and Linzess, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Headache (pain in head)
  3. Multiple allergies (allergy to multiple agents)
  4. Retching (strong involuntary effort to vomit)
  5. Rib fracture
  6. Skin irritation
  7. Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
  8. Smoke sensitivity
  9. Upper respiratory tract infection
  10. Urethral polyp

male:

  1. Abdominal distension
  2. Abdominal pain
  3. Dehydration (dryness resulting from the removal of water)
  4. Depression
  5. Device dislocation
  6. Diarrhoea
  7. Diplopia (double vision)
  8. Dizziness
  9. Dysphonia (speech disorder attributable to a disorder of phonation)
  10. Dyspnoea (difficult or laboured respiration)

What are the common drug interactions of Ceftriaxone and Linzess, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Post procedural complication
  2. Fibromyalgia (a long-term condition which causes pain all over the body)
  3. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  4. Hypercoagulation (increased tendency for clotting of the blood)
  5. Neuralgia (pain in one or more nerves)
  6. Suicidal ideation
  7. Colitis (inflammation of colon)
  8. Drug hypersensitivity
  9. Retching (strong involuntary effort to vomit)
  10. Skin irritation

30-39:

n/a

40-49:

n/a

50-59:

  1. Abscess limb (limb infection)
  2. Cellulitis (infection under the skin)
  3. Perirectal abscess
  4. Subcutaneous abscess
  5. Anal abscess
  6. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  7. Genital abscess (build up of pus in genital)
  8. Hospitalisation
  9. Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)
  10. Neoplasm (tumour)

60+:

  1. Fall
  2. Urinary tract infection
  3. Haemorrhage (bleeding)
  4. Headache (pain in head)
  5. Infusion site erythema (reddening of the skin at infusion site)
  6. Infusion site pain
  7. Infusion site rash
  8. Infusion site urticaria (rash of round, red welts on the skin at infusion site)
  9. Kidney infection
  10. Multiple allergies (allergy to multiple agents)

What are the existing conditions these people have? *

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 21 people, 42.86%
  2. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 18 people, 36.73%
  3. Immunodeficiency Common Variable: 12 people, 24.49%
  4. Dehydration (dryness resulting from the removal of water): 6 people, 12.24%
  5. High Blood Pressure: 5 people, 10.20%
  6. Nausea (feeling of having an urge to vomit): 4 people, 8.16%
  7. Hypotension (abnormally low blood pressure): 4 people, 8.16%
  8. Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 8.16%
  9. Fever: 4 people, 8.16%
  10. Pain: 3 people, 6.12%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftriaxone and Linzess?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ceftriaxone and Linzess:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Linzess:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ceftriaxone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Linzess and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium and linaclotide (the active ingredients of Ceftriaxone and Linzess, respectively), and Ceftriaxone and Linzess (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: